NCT06880354 - A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

CLL1 and CD38 Dual-Target CAR-T Cell Injection

This product is a lentiviral gene-modified autologous chimeric antigen receptor T-cell product that targets both CLL1 and CD38.

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, China, Tianjin